Eriko Padron-Regalado’s Post

Stay informed about what the FDA approves and what it doesn't. In a recent video, the FDA clarifies that it only approves prescription medications, not machinery, facilities, or other products and services that claim to be FDA approved. Check out the video for more information and stay up to date with the latest FDA news and regulations. #FDARumorControl

Stay informed about what the FDA approves and what it doesn't. In a recent video, the FDA clarifies that it only approves prescription medications, not machinery, facilities, or other products and services that claim to be FDA approved. Check out the video for more information and stay up to date with the latest FDA news and regulations. #FDARumorControl

Today marked the commencement of the ADA84 with the opening of the 84th Scientific Sessions by the Head of the FDA, Robert M. Califf. In his address, Califf underscored the FDA’s pivotal role in ensuring the safety and efficacy of pharmaceuticals and medical devices, safeguarding public health, and advancing regulatory science. He emphasized the critical importance of individual compliance, asserting it as the cornerstone for the successful implementation of health interventions and policy changes. While I concur with Califf’s perspective to a certain extent, the profound impact of weight loss medications observed recently raises a thought-provoking question. For centuries, recommendations centered around diet and exercise have not achieved the same level of efficacy as these new pharmacological interventions. This disparity prompts a significant debate: should we continue to rely predominantly on individual compliance, or should policymakers exert greater influence over our dietary and lifestyle choices to foster better health outcomes? #ADA84 #FDA #PublicHealth #WeightLossMedication #HealthPolicy #DietAndExercise #RegulatoryScience #IndividualCompliance #HealthDebate #ScientificSessions

Discover how a recent U.S. Court ruling on Ivermectin and COVID-19 could reshape regulatory interactions across industries. Our latest article delves into the implications of the “telling about vs. telling to” distinction, affecting sectors from healthcare to finance and beyond. Stay ahead with these key insights: https://lnkd.in/gky3hr3m

New Insights on the WHO-Listed Authority (WLA) Framework! The World Health Organization has introduced an evidence-based, transparent framework to strengthen regulatory reliance and improve access to quality-assured medical products worldwide. The study highlights the WLA framework’s role in promoting regulatory standards across diverse regions, supporting the Sustainable Development Goals for global health. By enhancing collaboration between regulatory authorities, the framework aims to ensure that safe and effective medical products reach those who need them most. Read more on PubMed: https://lnkd.in/d6RbgS4h #GlobalHealth #WHO #MedicalProducts #RegulatoryReliance #PublicHealth

Healing the Nation: How Drug Regulations Are Paving the Way for Accessible Healthcare – Regulatory Trends 2024 The full video is out now - https://lnkd.in/g9NjHbwv The Health and Drugs Regulatory session at Regulatory Trends 2024 examined the critical role of drug regulations in ensuring accessible healthcare across India. The distinguished panel included Shri CK Mishra (Ex-Secretary, Health & Family Welfare), Shri Rajesh Bhushan (Ex-Secretary, Health & Family Welfare), Shri A K Pradhan (Ex-Joint Drugs Controller, India), and Shri Indu Bhushan (Ex-CEO, National Health Authority). Key topics of discussion included: The impact of drug regulations on public health and healthcare accessibility Balancing innovation in pharmaceuticals with patient safety Policies driving affordable healthcare through regulatory oversight This session provided attendees with valuable insights into how India’s drug regulatory framework is evolving to foster a healthier, more accessible healthcare environment. #HealthcareRegulation #DrugRegulations #PublicHealth #AffordableHealthcare #RegulatoryTrends2024 #IndianRegulation #CUNSULT #PolicyInsights #HealthPolicy #Pharmaceuticals

Discover how the EU is combating falsified medicines to safeguard public health. From legislation to awareness campaigns, explore comprehensive strategies in place to protect patients. Read our latest blog to gain further insights! https://lnkd.in/gK8YsecC #EURegulation #FalsifiedMedicinesDirective #PharmaceuticalSafety #PharmaceuticalCompliance #EUHealthcare

🗣️ The EU must ensure timely and equitable #access to off-patent medicines after IP expiry for millions of #patients. 9 out of 10 products on the EU's critical medicines list are off-patent medicines. Yet, disparities in access across countries threaten public health as chronic diseases rise. 📈 Together, we should focus on: 🌱 Sustainable access & competitive market policies 💼 Swift adoption of the #PharmaLegislation for affordable off-patent medicines 🏭 EC first #100Days adoption of a #CriticalMedicinesAct 🧪 Investment in the EU as a global leader in #BiosimilarMedicines Let’s work for a stronger #EuropeanHealthUnion! 🤝 ➡️ Read more: https://buff.ly/4e5Ct9R ➡️ Check our manifesto: https://buff.ly/48gRX9S #MedicinesForEurope #Access4All

This week, global Health Authorities - MHRA, ANVISA, PMDA, FSSAI, TGA, USFDA, SFDA, EC, and MDA have rolled out crucial updates. Dive into the details with Freyr Regulatory Roundup: https://lnkd.in/gCfngXbY   #RegulatoryUpdates #HealthAuthorities #LifeSciences #FreyrRegulatoryRoundup #FreyrSolutions